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33 Abstract 
 
 
 
34 American trypanosomiasis or Chagas disease (CD) is a vector borne pathology caused by the 
 
35 parasite Trypanosoma cruzi (T. cruzi), which remains a serious global health problem. The 
 
36 current available treatment for CD is limited to two nitroderivatives with limited efficacy and 
 
37 several side effects. The rational design of ergosterol synthetic route inhibitors (e.g. CYP51 
 
38 inhibitors) represents a promising strategy for fungi and trypanosomatids, exhibiting excellent 
 
39 anti-T.cruzi activity in pre-clinical assays. In the present work, we evaluate through different 
 
40 approaches (molecular docking, structure activity relationships, CYP51 inhibitory assay, and 
 
41 phenotypic screenings in vitro and in vivo) the potency and selectivity of a novel CYP51 
 
42 inhibitor (compound 1) and its analogues against T.cruzi infection. Regarding anti-parasitic 
 
43 effect,  compound  1  was  active  in  vitro  with  EC50   3.86  and  4.00  µM  upon  intracellular 
 
44 (Tulahuen strain) and bloodstream forms (Y strain), respectively. In vivo assays showed that 
 
45 compound 1 reduced in 43 % the parasitemia peak but, unfortunately failed to promote animal 
 
46 survival. In order to promote an enhancement at the potency and pharmacological properties, 
 
47 17 new analogues were purchased and screened in vitro. Our findings demonstrated that five 
 
48 compounds were active against intracellular forms, highlighting compounds 1e and 1f, with 
 
49 EC50  2.20 and 2.70 µM, respectively, and selectivity indices (SI) = 50 and 36, respectively. 
 
50 Against bloodstream trypomastigotes, compound 1f reached an EC50 value of 20.62 µM, in a 
 
51 similar  range  to  Benznidazole,  but  with  low  SI  (3).  Although  improved  the  solubility  of 
 
52 compound 1, the analogue 1f did not enhance the potency in vitro neither promote better in 
 
53 vivo efficacy against mouse model of acute T.cruzi infection arguing for the synthesis of novel 
 
54 pyrazolo[3,4-e][1,4]thiazepin derivatives aiming to contribute for alternative therapies for CD 
 
55 
 
56 
 
57 Key-words: Chagas disease, Trypanosoma cruzi, CYP51 inhibitors and SAR studies. 
 
58 
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59 1. Introduction 
 
 
 
 
60 Chagas disease (CD) is a parasitic infection caused by the protozoan Trypanosoma 
 
61 cruzi (T. cruzi). Considered, as a worldwide public health problem due to migration 
 
62 flows and non-vector transmission routes, is estimates that about 6 to 7 million people 
 
63 are carries of T.cruzi and an average of over 12,000 people die every year [1, 2]. The 
 
64 main  mechanism  of  transmission  includes:  classical  vectorial  transmission  by 
 
65 triatomine bugs also known as blood sucking bugs, via congenital when the parasite is 
 
66 transmitted from mother to child, by oral contamination through ingesting the parasite 
 
67 on  contaminated  food  or  drink  and  through  iatrogenic  that  comprehend  blood 
 
68 transfusion or organ transplantation [3]. In many endemic countries like Brazil, vector 
 
69 and blood bank control measures lead to a drastic decreased in the number of new 
 
70 cases via classical vectorial route however, in last decades the oral transmission has 
 
71 emerged with epidemiological relevance in the Amazon region [2]. The CD has two 
 
72 phases, the acute phase appears soon after infection and is characterizing by the 
 
73 patent  parasitemia  and  mostly  displaying  oligosymptoms  ranging  from  flu-like  to 
 
74 intense myocarditis. Due to immune host response, there is a control of the parasite 
 
75 load and most patients move to a later stage called the chronic phase. Although most 
 
76 stay at the indeterminate stage, about 30-40% may develop symptoms after 10 to 20 
 
77 years post infection mainly related to cardiomyopathy associated or not to 
 
78 gastrointestinal effects [1,4]. The CD available treatment is restricted to two oral 
 
79 nitroheterocyclic compounds, nifurtimox and benznidazole (Bz) both introduced in 
 
80 clinical more than 50 years ago. Even though 25 million people are at risk of infection, 
 
81 according to the WHO, less than 1% of infected patients receive treatment [5]. Thus, 
 
82 the development of new effective drugs for Chagas disease is urgently needed, a 
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83 neglected pathology that mostly affects poor regions, and with low interest by the 
 
84 pharmaceutical  companies  due  to  the  low  monetary  welfares.  In  addition,  other 
 
85 limitations of using the current nitro-derivative drugs are: varying results according to 
 
86 the disease stage, treatment period and dose, age and geographical origin of the 
 
87 patients, side effects, besides a natural resistance profile of some parasite strains 
 
88 against nitro-derivatives [1, 6, 7, 8].  In order to face the limitations of the available 
 
89 therapy, several in vitro and in vivo studies of potentials new drug candidates for CD 
 
90 have been performed; some of these studies involving inhibitors of the ergosterol 
 
91 biosynthesis pathway. Differently from mammalian cells, in fungi and trypanosomatids, 
 
92 the cytochrome P450 enzyme or sterol 14α-demethylase (CYP51) pathway leads to 
 
93 formation of ergosterol-like products, which are essential for the survival of these 
 
94 parasites, producing viable membranes and making possible cell growth and division 
 
95 [9,10]. Recently, two CYP51 inhibitors first introduced as antifungal, Posaconazole 
 
96 and E1224 (the prodrug of Ravuconazole) and that later showed in vitro and in vivo 
 
97 efficacy against T. cruzi were moved for clinical trials upon chronic Chagas disease 
 
98 patients. Unsuccessfully, both inhibitors demonstrated therapeutic failure as compared 
 
99 to the reference drug, Bz [3, 11]. Among several possibilities, the disappointing results 
 
100 could be related to the lack of translation from in vitro and in vivo models as compared 
 
101 to the clinic trials as well as lack of pharmacological ideal conditions for human 
 
102 therapy. In fact, the efficacy of the CYP51 inhibitors may be related to the dose and 
 
103 time of exposure. It has been proposed that in clinical trials the administrated dose 
 
104 was  inferior  to  those  reached  in  pre-clinical  analysis  required  to  sustain  the 
 
105 trypanocidal effect. Also, longer drug therapy administration could have improved their 
 
106 clinical trial efficacy [12, 13, 14]. Then, this class of compounds should be more 
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107 studied in pre-clinical studies as the parasite is dependent on endogenous sterols and 
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108 
 
their products, reinforcing the purpose to study CYP51 inhibitors as potential treatment 
 
109 to CD [15, 16, 17]. Also, it must be considering others CYP51 inhibitors molecules, like 
 
110 imidazolic compounds VNI and VFV, that revealed very promising activity against a 
 
111 variety of T. cruzi strains in vitro and in vivo including a high stringent male mouse 
 
112 experimental model [10, 18 19, 20]. These findings reinforces the need to test the 
 
113 potential activity of novel inhibitors of CYP51 more potent and selective and that could 
 
114 be designed with optimized pharmacological properties, besides presenting reduced 
 
115 production cost, and which would allow treatment to be carried out for extended 
 
116 periods of time [10, 16, 20]. Thus, the aim of this study was to evaluate the anti- 
 
117 parasitic  activity  of  a  novel  pyrazolo[3,4-e][1,4]thiazepin  based  CYP51  inhibitor 
 
118 (compound 1) and its 17 analogues through different in silico, in vitro and in vivo 
 
119 
 
120 
analysis. 
 
 
 
121 2. Results and discussion 
 
 
 
122 Compound dataset was prepared using commercially available compounds, which 
 
123 cover the broad chemical landscape from the Asinex supplier of ZINC database 
 
124 (release 6). A dataset of 240,000 compounds was extracted (smiles format) based on 
 
125 “lead-like” properties such as Molecular weight between 150 and 500, H-bond donor 
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126 ≤5, H-bond acceptors ≤ 10, XlogP ≤ 5, Number of rotatable bonds ≤ 8. The minimum 
 
127 cut off for the molecular weight was chosen as 150 to avoid the selection of reagent 
 
128 like molecules. 2D-fingerprints in combination with tanimoto distances were used to 
 
129 select a diverse set of 100 compounds. These compounds were screened for their in 
 
130 vitro efficacy against intracellular T.cruzi amastigotes (strain: Silvio X10/7) in a single 
 
131 replicate at 5 µM. Five compounds that showed >80 % growth inhibition of intracellular 
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D 
E 
P  
C 
 
 
 
A 
 
132 
 
amastigotes were selected and a 10-point dose-response curves was carried out to 
 
133 determine their potency. We next assessed these compounds in the static-cidal and 
 
134 CYP51Tc  assays. Here, we discuss an interesting compound 1 (MW 413.93; cLogP 
 
135 4.84; H-bond acceptors 4; H-bond donors 2; Number of rotatable bonds 4) with a 
 
136 pyrazolo[3,4-e][1,4] thiazepin scaffold that showed strong CYP51Tc  inhibition, with 
 
137 activity comparable to Nifurtimox (Figure 1). This compound demonstrated an EC50 of 
 
138 0.4 µM against intracellular Silvio X10/7 parasites, cidal nature (rate of kill assay) with 
 
139 minimum cidal concentration (MCC) of 17 µM (Figure 2) and CYP51Tc inhibition with 
 
140 an IC50  of 0.1 µM (Figure 3). Both potency and cidal nature of this compound are 
 
141 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
142 
143 
144 
145 
146 
compared to Nifurtimox in Table 1. 
 
 
 
 
Figure 1. Molecular structures and ten point dose response curves of Nifurtimox and 
compound 1 with calculated potency values. The X-axis shows log of compound molar 
concentrations (M) and Y-axis shows the normalized activity based on the 
measurement of number of amastigotes per host cell. 
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Figure 2. Rate-of-kill assay for compound 1. Ten concentrations of compound were 
tested. Growth curves are shown for the compound at different concentrations 
indicated on the right hand side of each growth-line (µM). The level of infection was 
assessed every 24 hours for 96 hours. Dotted line represents concentration at which 
host cell toxicity was observed. All measurements are the average of three replicates. 
 
153 
154 
 
 
 
 
 
 
 
155 
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157 
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159 
 
 
 
160 
 
 
 
161 
Table 1. Potency assay and Static-cidal (SC) assay results for control compound 
Nifurtimox and compound 1 
 
Compound 
  ( 
Nifurtimox 
Compound 1 
*Maximum Percent Inhibition in the static cidal assay, only derived from compound concentrations that 
 
are not toxic to the host cells. 
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162 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
163 
 
Inhibitory effect of compound 1 on CYP51Tc activity 
 
164 
165 
166 
167 
Figure 3. T.cruzi CYP51 Inhibition Assay results for the compound 1 showing an IC50 value of 
0.1 µM.  ‘Y’ axis range 95.02 (std. error 4.94),  slope factor  1.70 (std.  error 0.39). Refer 
supporting information for test concentrations and associated data. 
 
168 Compound  1  was  tested  in  a  fluorescence  based  functional  assay  [21]  using 
 
169 recombinant expressed T.cruzi CYP51 (Tulahuen strain). Posaconazole was used as 
 
170 a reference compound. Compound 1 showed potent inhibition of T.cruzi CYP51 with 
 
171 IC50  value of 0.1 µM (Figure 3), whereas Posaconazole displayed an IC50  value of 
 
172 0.048 µM (refer supporting information). In a similar assay, Riley et al. [21] reported an 
 
173 IC50  value of 0.880 µM for Fluconazole. Overall compound 1 displayed over 8-fold 
 
174 more  inhibitory  activity  than  Fluconazole  and  2-fold  less  inhibitory  activity  than 
 
175 Posaconazole. 
 
 
176 As compound 1 showed good potency, cidal nature and strong CYP51Tc inhibition, we 
 
177 have selected this compound for further development. Initially we have assessed the 
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178 binding interactions of compound 1 with CYP51 using structure based drug design in 
 
179 order to gain deeper understanding of the interactions at the molecular level. Further, 
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A  
M  
D 
T 
P 
C 
 
180 
 
we have tested this compound against other strains of T.cruzi representatives of 
 
181 distinct parasite discrete type units - DTUs (Tulahuen – DTU VI and Y, DTU II). 
 
 
 
182 Binding Mode Prediction and Molecular interactions analysis of compound 1 
 
 
 
183 The ligand present in the CYP51Tc (PDB ID: 4C27) crystal structure was re-docked to 
 
184 validate the docking protocol, which was able to successfully reproduce the binding 
 
185 mode observed in the crystal structure. The RMSD value between the heavy atoms of 
 
186 the GLIDE-predicted pose and the crystallographic binding pose is 0.41 A°. We used 
 
187 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
188 
this docking protocol to dock compound 1 to CYP51Tc. 
 
189 
190 
191 
192 
193 
194 
195 
196 
197 
198 
199 
200 
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CYP51 of T. cruzi is represented as a transparent surface with cartoon secondary structure. 
Heme in yellow sticks, Fe in red CPK model. Compound 1 representation: Van der Waals 
surface around the compound 1 in mesh format, nitrogen in blue, oxygen in red, sulfur in yellow, 
chlorine in green. Heme iron co-ordination for both binding poses (A and B) in magenta 
dotted lines. π-π stacking interactions between pyrazole ring and heme macromolecule in 
teal dashed lines. Side chains of the amino acid residues (wire format) involved in interactions 
with compound 1 (A, B) through either π-π stacking (Teal dashed lines) or hydrogen bonding 
(magenta dashed lines). All structure based drug design Images in this article are generated 
using Schrödinger drug design software. 
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201 
 
Docking studies predicted two binding poses for compound 1 (Figure 4). In both the 
 
202 poses, the benzyloxy phenyl moiety attached to the basic scaffold pyrazolo-thiazepin 
 
203 mainly occupies the hydrophobic cleft making good van der Waals and hydrophobic 
 
204 interactions with the surrounding amino acids, but the basic scaffold is in different 
 
205 orientation, and the heme iron coordination is different.  In the top scoring pose 1 (XP 
 
206 GScore = - 9.44), the heme iron coordination is predicted with the carbonyl oxygen of 
 
207 the basic scaffold at a distance of 2.29 Å. The Pyrazole ring of the basic scaffold 
 
208 engages in π-π stacking interactions with the heme macrocycle and hydrogen bonds 
 
209 through N-H group with a hydroxyl oxygen of the B’/C loop residue Tyr116. In addition, 
 
210 the phenyl group undergoes a π-π stacking interaction with the phenyl ring of the B’ 
 
211 helix residue Tyr103. In the slightly lower scoring pose 2 (XP GScore = - 8.66), the 
 
212 heme iron coordination is predicted with the nitrogen atom of the pyrazole ring at a 
 
213 distance of 2.54 Å. Similar to pose 1, the Pyrazole ring undergoes π-π stacking 
 
214 interactions with the heme macrocycle and the phenyl group engages in π-π stacking 
 
215 interaction with the phenyl ring of the B’ helix residue Tyr103. In addition, the N-H 
 
216 group of the thiazepin ring hydrogen bonded to the carbonyl oxygen of the I-helix 
 
217 residue Ala291. The proposed hydrogen bond formation with Tyr116, π-π stacking 
 
218 interactions with the heme macrocycle and Tyr103 appear to mimic the 
 
219 posaconazole/flucanozole interactions with the CYP51Tc. Overall, both the poses are 
12 
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220 stabilized  in  the  binding  pocket  with  a  network  of  interactions  including  Fe- 
 
221 coordination, π-π stacking and hydrogen bonding interactions. It appears that these 
 
222 interactions play a dominant role in the binding affinity of compound 1. 
 
 
223 Evaluation of in vitro activity of compound 1 against Tulahuen and Y strains 
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224 
 
Compound 1 was further evaluated against intracellular forms of T cruzi (Tulahuen 
 
225 strain  transfected  with  the  β-galactosidase).  The  anti-parasitic  activity  of  this 
 
226 compound was measured to determine the EC50  values after 96 h of compound 
 
227 incubation. The data showed that compound 1 present considerable reduction in the 
 
228 number of parasite population, with an EC50 of 3.86 µM, which is comparable to the 
 
229 activity of reference compound (Bz) that reached an EC50 of ~2.63 µM (Table 2). Our 
 
230 data confirmed that this CYP51 inhibitor is able to act upon different parasite strains 
 
231 (Sylvio-X10/7 and Tulahuen), belonging also to different T.cruzi DTUs (I and VI, 
 
232 respectively), which is a very promising characteristic for a novel drug for CD [8]. 
 
 
233 
234 
Table 2. Activity (EC50  - Mean ± SD) against intracellular forms (Tulahuen B-Galactosidase 
  transfected strain) and bloodstream trypomastigotes of T.cruzi (2 and 24h - Y strain).   
 
 
Compound 
 
Activity against 
intracellular forms 
(EC50 µM) 
Activity against bloodstream 
trypomastigotes 
   (EC50 µM)    
2 h  24 h 
 
 
 
 
235 
Benznidazole 2.63 ± 0.49 >10 6.02 ± 1.47 
Compound 1 3.86 ± 0.26 >10 4.00 ± 0.35 
 
236 Next, as compound 1 displayed a potential activity in vitro against intracellular forms of 
 
237 T. cruzi (Tulahuen and Sylvio X10/7 strains), this compound was assayed against 
 
238 other relevant forms for mammalian infection, the bloodstream trypomastigotes, using 
 
239 also another parasite strain and DTU (Y strain, DTU II), under a time drug exposure 
 
240 incubation (2 and 24 h). The findings demonstrated that although both compound 1 
13 
  ACCEPTED MANUSCRIPT   
 
 
241 and Bz were not active after 2 h of incubation (EC50 of >10 µM), the CYP51 inhibitor 
 
242 showed trypanocidal effect after longer periods of incubation of BT, with an EC50 of ~4 
 
243 µM,  and  as  found  for  intracellular  parasites  (Tulahuen  strain),  with  comparable 
 
244 potency as Bz (Table 2) and Nifurtimox (Table 1). We have therefore evaluated a set 
 
245 of selected analogues (1a-1q, Table 3) with various functional groups that differ in 
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246 
 
electronic properties, position and steric properties as follows. The phenotypic effect of 
 
247 these compounds was first screened regarding their ability to reduce the infection 
 
248 levels against intracellular forms of T. cruzi (Tulahuen strain). Compounds with > 50 % 
 
249 reduction on infection levels using a single concentration (10-12 µM, corresponding 
 
250 the EC90  value of Bz, Table 3) were further subjected to potency assays (activity 
 
251 expressed as EC50 in Table 3). Toxicity profiles were determined against L929 cell 
 
252 cultures by incubating for 96 h with different concentrations of these compounds and 
 
253 then  cell  viability  evaluated  by  both  light  microscopy  and  colorimetric  assay 
 
254 (AlamarBlue tests) and expressing the respective LC50 values (Table 3). The ratio of 
 
255 LC50  and  EC50   values  is  presented  in  the  same  table  as  Selectivity  Index  (SI), 
 
256 indicating the quantity of compound that is active against the T.cruzi but is not toxic 
 
257 
 
 
 
258 
 
 
 
259 
 
 
 
260 
 
 
 
261 
 
 
 
262 
 
 
 
263 
 
 
 
264 
 
 
 
265 
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Ortho 
 
Meta 
 
Para 
Bz - - - - - - 89.3        
1 I Cl H H H -       
1a I H H Cl H - 14.88      
1b I F H H H - 63.64        
1c I H F H H - 70.68          
1d I H H F H - 32.42      
1e I Me H H H - 69.14          
1f I H Me H H - 89.25          
           
             
             
             
                 
             
             
             
           
           
           
 
N N 
 
 
 
267 
 
 
 
268 
 
 
 
269 Table  3.  Activity  (percentage  reduction  of  the  L929  culture  infection)  using  a  fixed 
 
270 concentration (10-12 µM), and anti-parasitic potency (EC50 - Mean ± SD – 96 h), mammalian 
 
271 host cell toxicity (L929 – 96 h) and selectivity against intracellular forms of T.cruzi (Tulahuen 
 
272 B-Galactosidase transfected strain). 
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Type 1 Type II 
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276 
 
 
277 The in vitro analysis revealed that five compounds (1b, 1c, 1e, 1f and 1k, Table 3) 
 
278 were able to decrease the intracellular parasite load in the infected L929 cell cultures, 
 
279 ranging 53 up to 89 % of reduction when concentration equivalent of EC90 of Bz was 
 
280 used  (Table  3).  These  compounds  also  displayed  low  toxicity  profile  against 
 
281 mammalian host cells (LC50  ≥ 50 µM, table 3). Compounds 1c, 1e and 1f did not 
 
282 induce loss of cellular viability after incubation for 96 h with doses up to 98 µM. 
 
283 Compound 1b maintained mammalian cell viability up to 200 µM. However, compound 
 
284 1k exhibited moderate toxicity with LC50 of ~50 µM. Compound 1e displayed high SI 
 
285 value  (>  50),  comparable  to  benznidazole.  Compounds  1b,  1c,  1f  displayed 
 
286 considerable  selectivity  with  SI  values  >38,  >19  and  >36  respectively.  Although 
 
287 compound 1k showed moderate potency against intracellular parasites, it showed 
 
288 poor selectivity (SI value = 4.7). An interesting observation from the above results 
 
289 (Table 3) is that compounds with ortho-substitutions displayed better selectivity and 
 
290 toxicity profiles when compared with meta-substituted compounds (compare SI and 
 
291 LC50 values of 1b with 1c and 1e with 1f) when assayed against intracellular forms of 
 
292 T. cruzi (Tulahuen strain). Compounds (1b, 1c, 1e, 1f and 1k, Table 3) showed good 
 
293 in vitro potency against intracellular forms of T. cruzi (Tulahuen β-Galactosidase 
 
294 transfected strain) were further tested for their activity against bloodstream 
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276 
 
 
295 trypomastigotes (Y strain). The results are shown in Table 4. After 2 h of incubation, all 
 
296 compounds showed an EC50  of >50 µM, similarly as benznidazole. After 24 h of 
 
297 incubation, compounds 1b, 1e and 1k did not show much improvement in the potency. 
 
298 Compound  1c  showed  large  variations  in  potency  possibly  due  to  compound 
 
299 instability. Interestingly, compound 1f showed (EC50 of ~20 µM) comparable activity to 
 
300 reference compound (EC50 of ~16 µM). The predicted binding pose of compound 1f is 
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301 
 
shown  in  Figure  5  (A).  The  orientation  of  the  binding  pose  and  the  receptor 
 
302 interactions are similar to compound 1. We have further evaluated all five compounds 
 
303 for their toxicity on primary cell cultures. Uninfected cardiac cells were incubated for 24 
 
304 h with different doses of these compounds and then cell viability evaluated by both 
 
305 light microscopy and colorimetric assay Prestoblue. 
 
 
306 
307 
Table 4. Activity (EC50 µM - Mean ± SD – 2 and 24h) against bloodstream trypomastigotes of 
T. cruzi (Y strain) besides toxicity upon cardiac cells (24h) and selectivity profile. 
Compound 
EC50 µM LC  µM SI (LC 
 
/EC 
 
– 24 h) µM 
2 h 24 h  50 50 50 
 
 
 
 
 
 
 
 
 
 
 
308 
Benznidazole >50 16.86 ± 3.34 >200 >12 
1b >50 >50 >200 >4 
1c >50 46.98 ± 10.93 93.97 ± 11.73 3.71 
1e >50 38.6 ± 6 >200 >5.2 
1f >50 20.62 ± 6.12 66 ± 25.82 3.20 
1k >50 39.37 ± 6.37 ND* ND* 
* ND: Not determined 
309 Compounds 1b, 1e did not induce loss of cellular viability after incubation for 24 h up 
310 to 200 µM (Table 4). Compounds 1c and 1f displayed low toxicity with LC50 values of 
311 ~93 and ~66 µM, respectively. 
312 Structure Activity Relationship (SAR) Analysis 
313 Next, the structure activity relationships of these compounds (1a-1q) is discussed 
314 according to their effect towards the infection level and the EC50 values against the 
315 intracellular  parasites.  Compounds  1a-1g  (Table  3)  that  differ  in  the  substitution 
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316 
pattern on the benzyl ring showed varied levels of potency. Compound 1 with ortho- 
317 chloro substitution displayed potency with an EC50  of ~3.86 µM. The switching of 
318 electron withdrawing, bulky chlorine from ortho- position (1) to para- position (1a) 
319 resulted in loss of potency. Replacement of ortho- chloro substituent with fluoro group 
320 (1b) displayed potency with an EC50  of ~5.30 µM, and the switching of fluoro group 
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321 
 
from ortho- (1b) to meta- position (1c) displayed similar potency. However, para- 
 
322 fluoro  substituted  compound  (1d)  showed  poor  potency.  Replacement  of  bulky, 
 
323 electron withdrawing ortho- chloro group (1) with isosteric, isolipophilic and electron 
 
324 donating methyl group (1e) displayed improved potency with an EC50 of ~2.20 µM, and 
 
325 the switching of methyl group from ortho- (1e) to meta- position (1f) retained the 
 
326 potency with an EC50 of ~2.70 µM. However, para- methyl substitution (1g) resulted in 
 
327 complete loss of potency, suggesting that the substitution pattern on the aromatic ring 
 
328 is  important. The  general  trend  of  activity  being  ortho-  and  meta-  substituted 
 
329 compounds are more potent than para- substituted compounds (compare 1 with 1a; 
 
330 compare  1b,  1c  with  1d;  compare  1e,  1f  with  1g).  Overall,  para-  substitutions 
 
331 (chloro/fluoro/methyl; 1a, 1d, 1g) on the benzyl ring generally displayed poor or no 
 
332 potency. Docking  studies on  these  compounds suggest that  para- substitutions 
 
333 protrude from the hydrophobic cleft towards a more solvent exposed area, while the 
 
334 ortho- and meta- substitutions allow better interactions with the hydrophobic cleft. This 
 
335 may explain why all substitutions at the para- position (1a, 1d, 1g) are not tolerated. 
 
336 The results suggest that the electronic properties of the substituents (chlorine moiety 
 
337 being  electron  withdrawing  and  methyl  moiety  being  electron  donating)  did  not 
 
338 influence the activity; however, the position specific and hydrophobic effects of the 
 
339 substituents on the benzyl ring are mainly involved in the variation in potency. We next 
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340 turned our attention to compounds 1h-1n with ortho- methoxy substituted phenyl ring. 
 
341 Compound 1h with unsubstituted benzyloxy group showed poor potency. Compounds 
 
342 with ortho- (1i, 1l), meta- (1j, 1m) and para- substitutions (1n) on the benzyl ring also 
 
343 displayed poor or no potency, the only exception is para-chloro substitution which 
 
344 resulted  in  a  comparatively  potent  compound  1k.  Our  binding  mode  analysis  of 
 
345 compounds 1i, 1j, 1l and 1m suggested that the introduction of a bulky methoxy group 
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346 
 
at the ortho- position restricts the conformation of the phenyl ring, thereby resulting in 
 
347 a different orientation, losing key interactions such as coordination with the heme iron, 
 
348 π-π stacking with Tyr103 and hydrogen bonding with Tyr116.  This appears to have 
 
349 resulted in loss of potency for these compounds. Interestingly, in the top scored 
 
350 binding poses of compounds 1h, 1k and 1n reverse binding modes were observed, 
 
351 where the pyrazolo [3,4-e] [1,4] thiazepin-7-one scaffold is placed in the hydrophobic 
 
352 binding cleft, benzyloxy moiety is placed in the B’/C loop and I helix region. This 
 
353 reverse binding mode do not appear to have favoured the potency of compounds 1h 
 
354 and 1n. However, for compound 1k, methoxy phenyl ring is in a different orientation 
 
355 compared to 1h and 1n, making strong hydrophobic interactions with the surrounding 
 
356 amino acids, thereby displaying moderate potency with an EC50 of ~10.85 µM. The 
 
357 
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Figure 5: A) Predicted binding pose of compound 1f (green sticks; XP GScore -8.58) in the 
hydrophobic tunnel. Heme iron co-ordination is represented as magenta dotted lines (2.30 Å). 
π-π stacking interactions between pyrazole ring and heme macromolecule in teal dashed 
lines. Side chains of the amino acid residuesTYR103 (wire format in black) TYR116 (wire 
format in magenta) involved in interactions with compound 1f through π-π stacking (teal 
dashed lines) and hydrogen bonding (magenta dashed lines)  respectively.  All  the interactions 
of this compound are similar to compound 1 (pose 1). B) Predicted reverse binding pose 
of 1k (orange sticks; XP GScore -10.64), pyrazolo [3,4-e] [1,4] thiazepin-7-one ring system is 
at the entrance of the tunnel and p-chlorophenyl moiety is oriented towards the heme; Heme 
in yellow sticks, Fe in red CPK model, Van der Waals surface around the compound 1k 
in mesh format, nitrogen in blue, oxygen in red, sulfur in yellow. Side chain carbonyl oxygen 
of the amino acid residue MET358 (wire format in magenta) is involved in 
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371 
372 
 
hydrogen bonding (magenta dashed lines) interaction with the NH moiety (pyrazole ring) of 
compound 1k. 
 
373 We finally probed the contribution of the substituted benzyl group of the pyrazolo [3,4- 
 
374 e] [1,4] thiazepin-7-one ring system towards the potency by screening a small set of 
 
375 analogues  with  aliphatic  substitutions  (Type  II).  Replacement of  benzyl  ring  with 
 
376 isopropyl (1o), n-propyl (1p) and allyl (1q) moieties completely abolished the potency 
 
377 altogether, suggesting that substituted benzyl ring plays an important role in stabilising 
 
378 the complex by forming strong hydrophobic interactions with the hydrophobic cleft. 
 
379 Moreover, perhaps these aliphatic substitutions do not fill the hydrophobic pocket 
 
380 enough, which was needed for potency and stability. Overall, these results suggest 
 
381 that the coordination with the heme iron, π-π stacking and hydrogen bond interactions 
 
382 in the B’helix and B’/C loop region, and the hydrophobic interactions with the residues 
 
383 surrounding  the  hydrophobic  tunnel  are  crucial  for  the  potency  of  this  series  of 
 
384 compounds. 
 
 
385 Overall,  1e  and 1f  were  the more promising compounds  regarding potency and 
 
386 selectivity profiles in both the intracellular (Tulahuen) and bloodstream trypomastigote 
 
387 (Y strain) forms of T. cruzi when compared to 1b, 1c, and 1k. Hence, as 1e showed 
 
388 poor solubility profile, we have further evaluated compounds 1 and 1f for their in vivo 
 
389 activity in mouse models of acute T.cruzi infection. 
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390 Evaluation of compounds in vivo 
 
 
391 The  in  vivo  efficacy  of  the  compound  1  was  evaluated  using  non-toxic  doses 
 
392 (previously determined in acute mice toxicity tests, showing an NOAEL > 50 mg/kg - 
 
393 i.p., data not shown) using 5, 10 and 20 mg/kg/daily doses. Bz was tested in parallel at 
 
394 its optimal dose of 100 mg/kg [22].  The administration of compound 1 for five days 
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425 mode of action of lead compound 1 is via inhibition of CYP51Tc.  Structure based drug 
 
426 design studies predicted the binding interactions of lead compound 1 with CYP51Tc to 
 
427 be  similar  to  Posaconazole  and  Fluconazole.  A  small  library  of  analogues  of 
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428 
 
compound 1 were evaluated for their potency and selectivity profiles against both the 
 
429 intracellular (Tulahuen) and bloodstream trypomastigote (Y strain) forms of T. cruzi. 
 
430 This resulted in interesting SARs that are in good agreement with our predicted 
 
431 binding  modes.  Compound  1f  showed  most  promising  anti-T.cruzi  activity.  Lead 
 
432 compound 1 and compound 1f were further evaluated for their in vivo activity in mouse 
 
433 models  of  acute  T.cruzi  infection.  Compound  1  is  only  partially  effective  in  the 
 
434 reduction of parasitemia possibly due to limited permeability and solubility 
 
435 characteristics. Compound 1f failed to reduce the parasitemia possibly due to poor 
 
436 permeability. Solubility and permeability are important physicochemical characteristics 
 
437 of  drug  like  compounds  that  reflect  their  bioavailability.  The  CYP51Tc   inhibitors 
 
438 described  here  provide  an  excellent  template  for  further  lead  optimization  of 
 
439 pyrazolo[3,4-e][1,4]thiazepin based analogues with improved solubility and 
 
440 permeability properties that may facilitate the anti-T.cruzi drug development. 
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452 
 
4. Experiment 
 
 
453 Compound database preparation: All the compounds in the dataset were processed 
 
454 through concord for the three-dimensional structure generation (mol2 files). 
 
455 Compounds with inappropriate isomeric specifications, compounds containing 
 
456 disallowed atoms in terms of valency and compounds with errors in ring definition are 
 
457 excluded from the co-ordinate generation. These compounds were converted into SLN 
 
458 format (SYBYL Line Notation) using UNITY translate module in SYBYL Version 7.3 
 
459 (Tripos) [23]. The selector module was used to generate two dimensional fingerprints 
 
460 and  tanimoto  distances.  All  the  compounds  in  this  study  were  purchased  from 
 
461 ASINEX. 
 
 
 
462 Molecular  docking: Molecular modelling studies  were  performed  primarily using 
 
463 Schrödinger drug design software suite (Schrödinger Release 2017-2) [24]. 
 
 
 
464 Protein preparation: The CYP51Tc (PDB: 4C27 with a resolution of 1.95 A°) protein 
 
465 structure was retrieved from Protein Data Bank. The protein was initially prepared 
 
466 using the Protein Preparation Wizard module of Schrödinger suite that prepares the 
 
467 protein by adding hydrogens,  assigning correct  bond  orders,  creating zero  bond 
 
468 orders to metals, fixing errors like missing side chains and adjusting the ionisation and 
 
469 tautomeric states  (via Epik).  We have deleted all the water molecules, chloride ions 
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470 and solvents (ethylene glycol) from the protein. Optimisation of the hydrogen bonding 
 
471 network and the orientation of the hydroxyl/thiol groups, terminal amide groups in Asn 
 
472 and Gln, and His states was carried out using the ProtAssign algorithm. Finally, 
 
473 restrained minimization was carried out using all atoms OPLS3 force fields, with 
 
474 converge heavy atoms to RMSD set to 0.3 Ă (default). 
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475 
 
Ligand Preparation: All the compounds were prepared using Ligprep module, which 
 
476 performed addition of hydrogens, 2D to 3D conversion, generation of ionization and 
 
477 tautomeric states including metal binding states (via Epik) at physiological pH 7.0  ± 
 
478 2.0, and also generated possible stereoisomers and ring conformations using default 
 
479 settings. All the compounds were energy minimised using OPLS3 force fields. 
 
 
480 Docking studies: The Receptor Grid generation was carried out by identifying the 
 
481 ligand in the 4C27 crystal structure and excluding it from the grid generation. The grid 
 
482 covers the entire binding site, which includes the heme iron macromolecule. Metal 
 
483 coordination constraint was applied at the Fe atom of the heme that defines an 
 
484 interaction between the ligand atom and the heme iron. Docking of compounds was 
 
485 carried out using Schrödinger GLIDE, in extra precision (XP) mode. 
 
 
486 CYP51 inhibitory assay: The CYP51 assay was carried out as described in [21]. All 
 
487 the potency assays and rate of kill assays with T. cruzi Silvio X10/7 strain were carried 
 
488 out as described in [25]. 
 
 
 
489 Spectroscopic data analysis and compound purity assessment by HPLC 
 
 
490 All 18 compounds were purchased directly from Asinex and used as supplied unless 
 
491 
 
492 
otherwise stated. Accurate mass and nominal mass measurements were performed 
using Bruker micrOTOF mass spectrometer. All 1HNMR spectra were recorded in 
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493 deutero-DMSO in 5 mm tubes, with tetramethylsilane as an internal standard, using a 
 
494 Bruker instrument. Chemical shifts (δ) are reported in ppm, and coupling constants (J) 
 
495 are given in Hz. Signals are represented by s (singlet), d (doublet), t (triplet), q 
 
496 (quartet), dq (double quartet) m (multiplet), bs (broad singlet), and dd (double doublet). 
 
497 HPLC was carried out using Agilent-1200 instrument. Column: Agilent eclipse plus 
 
498 C18 (150mm × 4.6mm, 5µm particle size), mobile phase 0.01% TFA in 
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499 
 
acetonitrile/water  (5%  to  95%  organic  over  20min  at  1mL/min),  10  µL  injection. 
 
500 
 
501 
 
502 
Detection was at 254nm, runtime 25 min. All the samples were prepared by dissolving 
the 5mg of compound in 0.7 mL of d6-DMSO (Sample solution prepared for HNMR 
was analyzed by HPLC). Blank (without the compound) d6-DMSO was used as a 
503 reference standard. Most of the compounds displayed >90% purity except compounds 
 
504 1h (77%), 1j (88%), 1l (87%) and 1n (84%). Refer to the supporting information for 
 
505 
 
506 
complete  data  on  HPLC  purity  analysis.  Isomer  ratios  of  the  compounds  were 
calculated from 1H-NMR spectra based on the CH3 signal (s) from substituted pyrazole 
507 ring of the one of the isomer against CH3 signal (s) from substituted pyrazole ring of 
 
508 the other isomer. 
 
 
509 4-[4-(2-Chloro-benzyloxy)-phenyl]-3,6-dimethyl-4,8-dihydro-1H-pyrazolo[3,4- 
 
510 
 
511 
e][1,4]thiazepin-7-one (Compound 1). Mixture of two isomers (98:2), δH/ppm (400 
MHz, d6-DMSO): Major isomer peaks are at 12.32 (1H, bs, NH from 3-pyrazole ring), 
512 9.66 (1H, s, NH from sec.amide), 7.62-7.55 (1H, m, Ar-H), 7.54-7.46 (1H, m, Ar-H), 
 
513 7.43-7.34 (2H, m, Ar-H), 7.21 (2H, d, J = 8.7 Hz, Ar-H), 6.94 (2H, d, J = 8.7 Hz, Ar-H), 
 
514 5.56 (1H, s, methine from [1,4] thiazepin ring), 5.11 (2H, s, CH2), 3.68 (1H, q, J = 7.0, 
 
515 methine from [1, 4] thiazepin ring), 1.91 (3H, s, CH3 from pyrazole ring), 1.19 (3H, d, J 
 
516 = 7.0 Hz, CH3 from [1, 4] thiazepin ring); Observable minor isomer peaks are at 9.86 
 
517 (1H, s, NH from sec.amide), 7.0 (2H, d, J = 8.8 Hz, Ar-H), 5.33 (1H, s, methine from 
 
518 [1, 4] thiazepin ring), 5.14 (2H, s, CH2), 1.69 (3H, s, CH3 from pyrazole ring), 1.08 (3H, 
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519 
 
520 
d, J = 7.1 Hz, CH3  from [1, 4] thiazepin ring). HRMS-m/z (ESI): found 414.1046 
(C21H22N3O2S [M + H]+) requires 414.0965. 
 
521 
 
522 
4-[4-(4-Chloro-benzyloxy)-phenyl]-3,6-dimethyl-4,8-dihydro-1H-pyrazolo[3,4- 
e][1,4]thiazepin-7-one (1a). Mixture of two isomers (96:4), δH/ppm (400 MHz, d6- 
26 
  ACCEPTED MANUSCRIPT   
 
 
523 
 
DMSO): Major isomer peaks are at 12.31 (1H, s, NH from 3-pyrazole ring), 9.65 (1H, 
 
524 s, NH from sec.amide), 7.48-7.41 (4H, m, Ar-H), 7.19 (2H, d, J = 8.7 Hz, Ar-H), 6.91 
 
525 (2H, d, J = 8.7 Hz, Ar-H), 5.55 (1H, s, methine from [1, 4] thiazepin ring), 5.05 (2H, s, 
 
526 CH2), 3.67 (1H, q, J = 7.04 Hz, methine from [1, 4] thiazepin ring), 1.90 (3H, s, CH3 
 
527 from  pyrazole  ring),  1.18  (3H,  d,  J  =  7.08  Hz,  CH3   from  [1,4]  thiazepin  ring); 
 
528 Observable minor isomer peaks are at 9.86 (1H, s, NH from sec.amide), 6.97 (2H, d, J 
 
529 = 8.7 Hz, Ar-H), 5.32 (1H, s, methine from [1, 4] thiazepin ring), 5.08 (2H, s, CH2), 1.68 
 
530 
 
531 
(3H, s, CH3 from pyrazole ring), 1.07 (3H, d, J = 7.2 Hz, CH3 from [1, 4] thiazepin ring). 
HRMS-m/z (ESI): found 414.1042 (C21H22N3O2S [M + H]+), requires 414.0965. 
 
532 
 
533 
4-[4-(2-Fluoro-benzyloxy)-phenyl]-3,6-dimethyl-4,8-dihydro-1H-pyrazolo[3,4- 
e][1,4]thiazepin-7-one (1b). Mixture of two isomers (95:5), δH/ppm (400 MHz, d6- 
534 DMSO): Major isomer peaks are at 12.31 (1H, bs, NH from 3-pyrazole ring), 9.66 (1H, 
 
535 s, NH from sec.amide), 7.58-7.50 (1H, m, Ar-H), 7.46-7.37 (1H, m, Ar-H), 7.29-7.15 
 
536 (2H, m, Ar-H) this multiplet is overlapped with doublet from the aromatic ring that is 
 
537 directly attached to the pyrazolo[3, 4-e][1, 4]thiazepin basic scaffold, 7.20 (2H, d, J = 
 
538 8.7 Hz, Ar-H), 6.94 (2H, d, J = 8.7 Hz, Ar-H), 5.56 (1H, s, methine from [1, 4] thiazepin 
 
539 ring), 5.09 (2H, s, CH2), 3.68 (1H, q, J = 7.0 Hz, methine from [1, 4] thiazepin ring), 
 
540 1.91 (3H, s, CH3 from pyrazole ring), 1.19 (3H, d, J = 7.0 Hz, CH3 from [1,4] thiazepin 
 
541 ring); Observable minor isomer peaks are at 9.85 (1H, s, NH from sec.amide), 6.94 
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542 (2H, d, J = 8.7 Hz, Ar-H), 5.56 (1H, s, methine from [1, 4] thiazepin ring), 5.11 (2H, s, 
 
543 
 
544 
 
545 
CH2), 1.68 (3H, s, CH3 from pyrazole ring), 1.07 (3H, d, J = 7.2 Hz, CH3 from [1, 4] 
thiazepin ring). 19FNMR: 118.41 ppm. HRMS-m/z (ESI): found 398.1341 
(C21H21FN3O2S [M + H]+), requires 398.1260. 
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546 
 
547 
 
4-[4-(3-Fluoro-benzyloxy)-phenyl]-3,6-dimethyl-4,8-dihydro-1H-pyrazolo[3,4- 
e][1,4]thiazepin-7-one (1c). Mixture of two isomers (86:14), δH/ppm (400 MHz, d6- 
548 DMSO): Major isomer peaks are at 12.30 (1H, bs, NH from 3-pyrazole ring), 9.65 (1H, 
 
549 s, NH from sec.amide), 7.47-7.38 (1H, m, Ar-H), 7.31-7.23 (2H, m, Ar-H), 7.16-7.12 
 
550 (1H, m, Ar-H) this multiplet is overlapped with doublet from the aromatic ring that is 
 
551 directly attached to the pyrazolo[3, 4-e][1, 4]thiazepin basic scaffold, 7.19 (2H, d, J = 
 
552 8.7 Hz, Ar-H), 6.92 (2H, d, J = 8.7 Hz, Ar-H), 5.55 (1H, s, methine from [1, 4] thiazepin 
 
553 ring), 5.08 (2H, s, CH2), 3.67 (1H, q, J = 7.03 Hz, methine from [1, 4] thiazepin ring), 
 
554 1.90 (3H, s, CH3 from pyrazole ring), 1.19 (3H, d, J = 7.08 Hz, CH3 from [1,4] thiazepin 
 
555 ring); Observable minor isomer peaks are at 9.85 (1H, s, NH from sec.amide), 6.97 
 
556 (2H, d, J = 8.7 Hz, Ar-H), 5.32 (1H, s, methine from [1, 4] thiazepin ring), 5.10 (2H, s, 
 
557 
 
558 
 
559 
CH2), 3.24 (1H, q, J =  1.67 Hz),1.67 (3H, s, CH3 from pyrazole ring), 1.06 (3H, d, J = 
 
7.2 Hz, CH3 from [1, 4] thiazepin ring). 19FNMR: 113.20 ppm. HRMS-m/z (ESI): found 
398.1341 (C21H21FN3O2S [M + H]+), requires 398.1260. 
 
 
560 
 
561 
4-[4-(4-Fluoro-benzyloxy)-phenyl]-3,6-dimethyl-4,8-dihydro-1H-pyrazolo[3,4- 
e][1,4]thiazepin-7-one (1d). Mixture of two isomers (96:4), δH/ppm (400 MHz, d6- 
562 DMSO): Major isomer peaks are at 12.33 (1H, bs, NH from 3-pyrazole ring), 9.65 (1H, 
 
563 s, NH from sec.amide), 7.54-7.44 (2H, m, Ar-H), 7.25-7.16 (4H, m, Ar-H), 6.91 (2H, d, 
 
564 J = 8.7 Hz, Ar-H), 5.55 (1H, s, methine from [1, 4] thiazepin ring), 5.03 (2H, s, CH2), 
 
565 3.67 (1H, q, J = 7.02 Hz, methine from [1, 4] thiazepin ring), 1.90 (3H, s, CH3  from 
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566 pyrazole ring), 1.19 (3H, d, J = 7.08 Hz, CH3  from [1,4] thiazepin ring); Observable 
 
567 minor isomer peaks are at 9.85 (1H, s, NH from sec.amide), 6.96 (2H, d, J = 8.7 Hz, 
 
568 Ar-H), 5.32 (1H, s, methine from [1, 4] thiazepin ring), 5.05 (2H, s, CH2), 1.67 (3H, s, 
 
569 CH3  from pyrazole ring), 1.07 (3H, d, J = 7.1 Hz, CH3  from [1, 4] thiazepin ring). 
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570 
 
19FNMR: 114.49 ppm. HRMS- m/z (ESI): found 398.1340 (C21H21FN3O2S [M + H]+), 
 
571 requires 398.1260. 
 
 
 
572 
 
573 
3,6-Dimethyl-4-[4-(2-methyl-benzyloxy)-phenyl]-4,8-dihydro-1H-pyrazolo[3,4- 
e][1,4]thiazepin-7-one (1e). Mixture of two isomers (97:3), δH/ppm (400 MHz, d6- 
574 DMSO): Major isomer peaks are at 12.30 (1H, bs, NH from 3-pyrazole ring), 9.66 (1H, 
 
575 s, NH from sec.amide), 7.38 (1H, d, J = 7.30 Hz, Ar-H), 7.28-7.14 (5H, m, Ar-H), 6.94 
 
576 (2H, d, J = 8.7 Hz, Ar-H), 5.56 (1H, s, methine from [1, 4] thiazepin ring), 5.03 (2H, s, 
 
577 CH2), 3.68 (1H, q, J = 7.0 Hz, methine from [1, 4] thiazepin ring), 2.30 (3H, s, ortho 
 
578 CH3), 1.91 (3H, s, CH3  from pyrazole ring), 1.19 (3H, d, J = 7.0 Hz, CH3  from [1,4] 
 
579 thiazepin  ring);  Observable  minor  isomer  peaks  are  at  9.85  (1H,  s,  NH  from 
 
580 sec.amide), 6.99 (2H, d, J = 8.7 Hz, Ar-H), 5.32 (1H, s, methine from [1, 4] thiazepin 
 
581 ring), 5.06 (2H, s, CH2), 2.32 (3H, s, ortho CH3),  1.68 (3H, s, CH3 from pyrazole ring), 
 
582 
 
583 
1.08 (3H, d, J = 7.2 Hz, CH3  from [1, 4] thiazepin ring). HRMS- m/z (ESI): found 
394.1586 (C22H24N3O2S [M + H]+), requires 394.1511. 
 
584 
 
585 
3,6-Dimethyl-4-[4-(3-methyl-benzyloxy)-phenyl]-4,8-dihydro-1H-pyrazolo[3,4- 
e][1,4]thiazepin-7-one (1f). Mixture of two isomers (66:34), δH/ppm (400 MHz, d6- 
586 DMSO): Major isomer peaks are at 12.31 (1H, bs, NH from 3-pyrazole ring), 9.65 (1H, 
 
587 s, NH from sec.amide), 7.32-7.09 (6H, m, Ar-H), 6.91 (2H, d, J = 8.8 Hz, Ar-H), 5.55 
 
588 (1H, s, methine from [1, 4] thiazepin ring), 5.01 (2H, s, CH2), 3.67 (1H, q, J = 7.0 Hz, 
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589 methine from [1, 4] thiazepin ring), 2.31 (3H, s, meta CH3), 1.90 (3H, s, CH3  from 
 
590 pyrazole ring), 1.19 (3H, d, J = 7.0 Hz, CH3  from [1, 4] thiazepin ring); Observable 
 
591 minor isomer peaks are at 9.85 (1H, s, NH from sec.amide), 7.32-7.09 (6H, m, Ar-H), 
 
592 6.96 (2H, d, J = 8.8 Hz, Ar-H), 5.32 (1H, s, methine from [1,4] thiazepin ring), 5.03(2H, 
 
593 s, CH2), 3.24 (1H, q, J = 7.2 Hz methine from [1, 4] thiazepin ring), 2.31 (3H, s, meta 
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594 
 
595 
 
CH3),  1.70 (3H, s, CH3  from pyrazole ring), 1.01 (3H, d, J = 7.2 Hz, CH3  from [1,4] 
thiazepin ring). HRMS; m/z (ES): found 394.1580 (C22H24N3O2S [M + H]+), requires 
596 394.1511. 
 
 
 
597 
 
598 
3,6-Dimethyl-4-[4-(4-methyl-benzyloxy)-phenyl]-4,8-dihydro-1H-pyrazolo[3,4- 
e][1,4]thiazepin-7-one (1g). Mixture of two isomers (69:31), δH/ppm (400 MHz, d6- 
599 DMSO): Major isomer peaks are at 12.30 (1H, bs, NH from 3-pyrazole ring), 9.65 (1H, 
 
600 s, NH from sec.amide), 7.36-7.27 (2H, m, Ar-H), 7.22-7.12 (4H, m, Ar-H), 6.90 (2H, d, 
 
601 J = 8.7 Hz, Ar-H), 5.55 (1H, s, methine from [1, 4] thiazepin ring), 5.00 (2H, s, CH2), 
 
602 3.67 (1H, q, J = 7.0 Hz, methine from [1, 4] thiazepin ring), 2.29 (3H, s, para CH3), 
 
603 1.90 (3H, s, CH3 from pyrazole ring), 1.18 (3H, d, J = 7.08 Hz, CH3 from [1,4] thiazepin 
 
604 ring); Observable minor isomer peaks are at 9.85 (1H, s, NH from sec.amide), 7.36- 
 
605 7.27 (2H, m, Ar-H), 7.22-7.12 (4H, m ,Ar-H), 6.94 (2H, d, J = 8.8 Hz, Ar-H), 5.31 (1H, 
 
606 s, methine from [1, 4] thiazepin ring), 5.01 (2H, s, CH2), 3.24 (1H, q, J = 7.2 Hz 
 
607 methine from [1, 4] thiazepin ring), 2.30 (3H, s, para CH3), 1.67 (3H, s, CH3  from 
 
608 
 
609 
pyrazole ring), 1.07 (3H, d, J = 7.2 Hz, CH3 from [1,4] thiazepin ring). HRMS; m/z (ES): 
found 394.1582 (C22H24N3O2S [M + H]+) requires 394.1511. 
 
610 
 
611 
4-(4-Benzyloxy-3-methoxy-phenyl)-3,6-dimethyl-4,8-dihydro-1H-pyrazolo[3,4- 
e][1,4]thiazepin-7-one (1h). Mixture of two isomers (63:37), δH/ppm (400 MHz, d6- 
612 DMSO): First isomer peaks are at 12.30 (1H, bs, NH from 3-pyrazole ring), 9.66 (1H, 
 
613 s, NH from sec.amide), 7.50-7.27 (5H, m, Ar-H), 7.01-6.89 (2H, m, Ar-H), 6.75 (1H, dd, 
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614 J = 8.3 + 2.0 Hz, Ar-H), 5.51 (1H, s, methine from [1, 4] thiazepin ring), 5.02 (2H, s, 
 
615 CH2), 3.71 (3H, s, OCH3), 3.67 (1H, q, J = 7.0 Hz, methine from [1, 4] thiazepin ring), 
 
616 1.95 (3H, s, CH3 from pyrazole ring), 1.19 (3H, d, J = 7.04 Hz, CH3 from [1,4] thiazepin 
 
617 ring); Observable second isomer peaks are at 9.84 (1H, s, NH from sec.amide), 7.50- 
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618 
 
7.27 (5H, m, Ar-H), 7.01-6.89 (2H, m ,Ar-H), 6.63 (1H, dd, J = 8.3 + 1.8 Hz, Ar-H), 5.30 
 
619 (1H, s, methine from [1, 4] thiazepin ring), 5.04 (2H, s, CH2), 3.73 (3H, s, OCH3), 3.30 
 
620 (1H, q, methine from [1, 4] thiazepin ring, this peak is partly covered by water peak 
 
621 
 
622 
from DMSO), 1.68 (3H, s, CH3 from pyrazole ring), 1.09 (3H, d, J = 7.2 Hz, CH3 from 
[1,4]  thiazepin  ring).  HRMS;  m/z  (ES):  found  410.1539  (C22H24N3O3S  [M  +  H]+) 
623 requires 410.1460. 
 
 
 
624 4-[4-(2-Chloro-benzyloxy)-3-methoxy-phenyl]-3,6-dimethyl-4,8-dihydro-1H- 
 
625 
 
626 
pyrazolo[3,4-e][1,4]thiazepin-7-one (1i). Mixture of two isomers (72:28), δH/ppm (400 
MHz, d6-DMSO): Major isomer peaks are at 12.31 (1H, bs, NH from 3-pyrazole ring), 
627 9.67 (1H, s, NH from sec.amide), 7.63-7.54 (1H, m, Ar-H), 7.53-7.46 (1H, m, Ar-H), 
 
628 7.42-7.34 (2H, m, Ar-H), 7.02-6.90 (2H, m, Ar-H), 6.77 (1H, dd, J = 8.3 + 2.0 Hz, Ar- 
 
629 H), 5.53 (1H, s, methine from [1, 4] thiazepin ring), 5.10 (2H, s, CH2), 3.72 (3H, s, 
 
630 OCH3), 3.67 (1H, q, J = 7.0 Hz, methine from [1, 4] thiazepin ring), 1.96 (3H, s, CH3 
 
631 from pyrazole ring), 1.19 (3H, d, J = 7.0 Hz, CH3 from [1,4] thiazepin ring); Observable 
 
632 minor isomer peaks are at 9.84 (1H, s, NH from sec.amide), 7.63-7.54 (1H, m, Ar-H), 
 
633 7.53-7.46 (1H, m, Ar-H), 7.42-7.34 (2H, m, Ar-H), 7.02-6.90 (2H, m, Ar-H), 6.65 ((1H, 
 
634 dd, J = 8.3 + 1.80 Hz, Ar-H), 5.31 (1H, s, methine from [1, 4] thiazepin ring), 5.11 (2H, 
 
635 s, CH2), 3.74 (3H, s, OCH3), 3.30 (1H, q, methine from [1, 4] thiazepin ring, this peak 
 
636 is partly covered by water peak from DMSO), 1.69 (3H, s, CH3  from pyrazole ring), 
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637 
 
638 
1.09 (3H, d, J = 7.10 Hz, CH3  from [1,4] thiazepin ring). HRMS; m/z (ES): found 
444.1159 (C22H23ClN3O3S [M + H]+) requires 444.1070. 
 
639 4-[4-(3-Chloro-benzyloxy)-3-methoxy-phenyl]-3,6-dimethyl-4,8-dihydro-1H- 
 
640 
 
641 
pyrazolo[3,4-e][1,4]thiazepin-7-one (1j). Mixture of two isomers (68:32), δH/ppm (400 
MHz, d6-DMSO): First isomer peaks are at 12.30 (1H, bs, NH from 3-pyrazole ring), 
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642 
 
9.67 (1H, s, NH from sec.amide), 7.52-7.34 (4H, m, Ar-H), 7.03-6.87 (2H, m, Ar-H), 
 
643 6.76 (1H, dd, J = 8.3 + 2.1 Hz, Ar-H), 5.52 (1H, s, methine from [1, 4] thiazepin ring), 
 
644 5.05 (2H, s, CH2), 3.72 (3H, s, OCH3), 3.67 (1H, q, J = 7.0 Hz, methine from [1,4] 
 
645 thiazepin ring), 1.95 (3H, s, CH3  from pyrazole ring), 1.20 (3H, d, J = 7.04 Hz, CH3 
 
646 from [1,4] thiazepin ring); Observable second isomer peaks are at 9.84 (1H, s, NH 
 
647 from sec.amide), 7.52-7.34 (4H, m, Ar-H), 7.03-6.89 (2H, m ,Ar-H), 6.64 (1H, dd, J = 
 
648 8.2 + 1.9 Hz, Ar-H), 5.30 (1H, s, methine from [1, 4] thiazepin ring), 5.10 (2H, s, CH2), 
 
649 
 
650 
3.74 (3H, s, OCH3), 1.68 (3H, s, CH3 from pyrazole ring), 1.09 (3H, d, J = 7.2 Hz, CH3 
 
from [1, 4] thiazepin ring). HRMS; m/z (ES): found 444.1154 (C22H23ClN3O3S [M + H]+) 
 
651 requires 444.1070. 
 
 
652 4-[4-(4-Chloro-benzyloxy)-3-methoxy-phenyl]-3,6-dimethyl-4,8-dihydro-1H- 
 
653 
 
654 
pyrazolo[3,4-e][1,4]thiazepin-7-one (1k). Mixture of two isomers (68:32), δH/ppm (400 
MHz, d6-DMSO): major isomer peaks are at 12.31 (1H, bs, NH from 3-pyrazole ring), 
655 9.66 (1H, s, NH from sec.amide), 7.51-7.41 (4H, m, Ar-H), 7.00-6.87 (2H, m, Ar-H), 
 
656 6.75 (1H, dd, J = 8.4 + 2.0 Hz, Ar-H), 5.51 (1H, s, methine from [1, 4] thiazepin ring), 
 
657 5.03 (2H, s, CH2), 3.71 (3H, s, OCH3), 3.67 (1H, q, J = 7.0 Hz, methine from [1,4] 
 
658 thiazepin ring), 1.95 (3H, s, CH3 from pyrazole ring), 1.19 (3H, d, J = 7.0 Hz, CH3 from 
 
659 [1,4] thiazepin ring); Observable minor isomer peaks are at 9.84 (1H, s, NH from 
 
660 sec.amide), 7.51-7.41 (4H, m, Ar-H), 7.00-6.87 (2H, m, Ar-H), 6.63 (1H, dd, J = 8.2 + 
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661 1.8 Hz, Ar-H), 5.30 (1H, s, methine from [1, 4] thiazepin ring), 5.04 (2H, s, CH2), 3.73 
 
662 (3H, s, OCH3), 3.30 (1H, q, methine from [1, 4] thiazepin ring, this peak is partly 
 
663 covered by water peak from DMSO), 1.67 (3H, s, CH3 from pyrazole ring), 1.09 (3H, d, 
 
664 
 
665 
J  =  7.2  Hz,  CH3   from  [1,4]  thiazepin  ring).  HRMS;  m/z  (ES):  found  444.1157 
(C22H23ClN3O3S [M + H]+) requires 444.1070. 
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666 
 
4-[3-Methoxy-4-(2-methyl-benzyloxy)-phenyl]-3,6-dimethyl-4,8-dihydro-1H- 
 
667 
 
668 
pyrazolo[3,4-e][1,4]thiazepin-7-one (1l). Mixture of two isomers (66:34), δH/ppm (400 
MHz, d6-DMSO): major isomer peaks are at 12.30 (1H, bs, NH from 3-pyrazole ring), 
669 9.67 (1H, s, NH from sec.amide), 7.43-7.34 (1H, m, Ar-H), 7.28-7.14 (3H, m, Ar-H), 
 
670 7.03-6.91 (2H, m, Ar-H), 6.77 (1H, dd, J = 8.3 + 2.0 Hz, Ar-H), 5.52 (1H, s, methine 
 
671 from [1,4] thiazepin ring), 5.00 (2H, s, CH2), 3.70 (3H, s, OCH3), 3.67 (1H, q, J = 7.0 
 
672 Hz, methine from [1,4] thiazepin ring), 2.30 (3H, s, ortho CH3), 1.96 (3H, s, CH3 from 
 
673 pyrazole ring), 1.19 (3H, d, J = 7.0 Hz, CH3  from [1, 4] thiazepin ring); Observable 
 
674 minor isomer peaks are at 9.84 (1H, s, NH from sec.amide), 7.43-7.34 (1H, m, Ar-H), 
 
675 7.28-7.14 (3H, m, Ar-H), 7.03-6.91 (2H, m, Ar-H), 6.65 (1H, dd, J = 8.2 + 1.8 Hz, Ar- 
 
676 H), 5.30 (1H, s, methine from [1,4] thiazepin ring), 5.02 (2H, s, CH2), 3.72 (3H, s, 
 
677 OCH3), 3.30 (1H, q, methine from [1, 4] thiazepin ring, this peak is partly covered by 
 
678 water peak from DMSO), 2.32 (3H, s, ortho CH3), 1.69 (3H, s, CH3 from pyrazole ring), 
 
679 
 
680 
1.10 (3H, d, J = 7.12 Hz, CH3  from [1, 4] thiazepin ring). HRMS; m/z (ES): found 
424.1688 (C23H26N3O3S [M + H]+) requires 424.1617. 
 
681 4-[3-Methoxy-4-(3-methyl-benzyloxy)-phenyl]-3,6-dimethyl-4,8-dihydro-1H- 
 
682 
 
683 
pyrazolo[3,4-e][1,4]thiazepin-7-one (1m). Mixture of two isomers (65:35), δH/ppm (400 
MHz, d6-DMSO): major isomer peaks are at 12.30 (1H, bs, NH from 3-pyrazole ring), 
684 9.66 (1H, s, NH from sec.amide), 7.30-7.10 (4H, m, Ar-H), 7.00-6.87 (2H, m, Ar-H), 
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685 6.74 (1H, dd, J = 8.3 + 2.0 Hz, Ar-H), 5.51 (1H, s, methine from [1, 4] thiazepin ring), 
 
686 5.00 (2H, s, CH2), 3.71 (3H, s, OCH3), 3.66 (1H, q, J = 7.07 Hz, methine from [1,4] 
 
687 thiazepin ring), 2.31 (3H, s, meta CH3), 1.95 (3H, s, CH3 from pyrazole ring), 1.19 (3H, 
 
688 d, J = 7.04 Hz, CH3 from [1, 4] thiazepin ring); Observable minor isomer peaks are at 
 
689 9.84 (1H, s, NH from sec.amide), 7.30-7.10 (4H, m, Ar-H), 7.00-6.87 (2H, m, Ar-H), 
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690 
 
6.62 (1H, dd, J = 8.4 + 2.0 Hz, Ar-H), 5.30 (1H, s, methine from [1,4] thiazepin ring), 
 
691 5.00 (2H, s, CH2), 3.73 (3H, s, OCH3), 3.30 (1H, q, methine from [1,4] thiazepin ring, 
 
692 this peak is partly covered by water peak from DMSO), 2.31 (3H, s, meta CH3), 1.68 
 
693 
 
694 
(3H, s, CH3 from pyrazole ring), 1.09 (3H, d, J = 7.2 Hz, CH3 from [1, 4] thiazepin ring). 
HRMS; m/z (ES): found 424.1687 (C23H26N3O3S [M + H]+) requires 424.1617. 
 
695 4-[3-Methoxy-4-(4-methyl-benzyloxy)-phenyl]-3,6-dimethyl-4,8-dihydro-1H- 
 
696 
 
697 
pyrazolo[3,4-e][1,4]thiazepin-7-one (1n). Mixture of two isomers (62:38), δH/ppm (400 
MHz, d6-DMSO): major isomer peaks are at 12.29 (1H, bs, NH from 3-pyrazole ring), 
698 9.66 (1H, s, NH from sec.amide), 7.35-7.26 (2H, m Ar-H), 7.24-7.14 (2H, m, Ar-H), 
 
699 7.00-6.87 (2H, m, Ar-H), 6.74 (1H, dd, J = 8.3 + 2.1 Hz, Ar-H), 5.51 (1H, s, methine 
 
700 from [1,4] thiazepin ring), 4.97 (2H, s, CH2), 3.70 (3H, s, OCH3), 3.66 (1H, q, J = 7.0 
 
701 Hz, methine from [1,4] thiazepin ring), 2.29 (3H, s, para CH3), 1.95 (3H, s, CH3 from 
 
702 pyrazole ring), 1.18 (3H, d, J = 7.0 Hz, CH3  from [1, 4] thiazepin ring); Observable 
 
703 minor isomer peaks are at 9.84 (1H, s, NH from sec.amide), 7.35-7.26 (2H, m Ar-H), 
 
704 7.24-7.14 (2H, m, Ar-H), 7.00-6.87 (2H, m, Ar-H), 6.62 (1H, dd, J = 8.3 + 1.8 Hz, Ar- 
 
705 H), 5.30 (1H, s, methine from [1,4] thiazepin ring), 4.98 (2H, s, CH2), 3.72 (3H, s, 
 
706 OCH3), 3.29 (1H, q, methine from [1, 4] thiazepin ring, this peak is partly covered by 
 
707 water peak from DMSO), 2.30 (3H, s, para CH3), 1.68 (3H, s, CH3 from pyrazole ring), 
 
708 
 
709 
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1.0
9 
(3H, d, J = 7.12 Hz, CH3  from [1, 4] thiazepin ring). HRMS; m/z (ES): found 
424.1687 (C23H26N3O3S [M + H]+) requires 424.1617. 
 
710 
 
711 
4-(4-Isopropoxy-phenyl)-3,6-dimethyl-4,8-dihydro-1H-pyrazolo[3,4-e][1,4]thiazepin-7- 
one (1o). Mixture of two isomers (97:3), δH/ppm (400 MHz, d6-DMSO): major isomer 
712 peaks are at 12.30 (1H, s, NH from 3-pyrazole ring), 9.64 (1H, s, NH from sec.amide), 
 
713 7.15 (2H, d, J = 8.68 Hz, Ar-H), 6.80 (2H, d, J = 8.76 Hz, Ar-H), 5.54 (1H, s, methine 
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714 
 
from [1, 4] thiazepin ring), 4.54 (1H, hept, CH of isopropyl), 3.67 (1H, q, J = 7.0 Hz, 
 
715 methine from [1, 4] thiazepin ring), 1.90 (3H, s, CH3 from pyrazole ring), 1.23 (6H, d, J 
 
716 = 6.0 Hz, (CH3)2 of isopropyl), 1.18 (3H, d, J = 7.08 Hz, CH3 from [1,4] thiazepin ring); 
 
717 Observable minor isomer peaks are at 9.83 (1H, s, NH from sec.amide), 6.85 (2H, d, J 
 
718 = 8.7 Hz, Ar-H), 5.30 (1H, s, methine from [1, 4] thiazepin ring), 1.67 (3H, s, CH3 from 
 
719 
 
720 
pyrazole ring), 1.07 (3H, d, J = 7.1 Hz, CH3  from [1, 4] thiazepin ring). HRMS; m/z 
(ES): found 332.1428 (C17H22N3O2S [M + H]+) requires 332.1354. 
 
721 
 
722 
3,6-Dimethyl-4-(4-propoxy-phenyl)-4,8-dihydro-1H-pyrazolo[3,4-e][1,4]thiazepin-7-one 
 
(1p). Mixture of two isomers (85:15), δH/ppm (400 MHz, d6-DMSO): major isomer 
 
723 peaks are at 12.30 (1H, s, NH from 3-pyrazole ring), 9.65 (1H, s, NH from sec.amide), 
 
724 7.16 (2H, d, J = 8.7 Hz, Ar-H), 6.82 (2H, d, J = 8.7 Hz, Ar-H), 5.55 (1H, s, methine 
 
725 from [1, 4] thiazepin ring), 3.87 (2H, t, J = 6.52 Hz, OCH2 of n-propyl), 3.67 (1H, q, J = 
 
726 7.0 Hz, methine from [1, 4] thiazepin ring), 1.90 (3H, s, CH3 from pyrazole ring), 1.76- 
 
727 1.62 (2H, m, CH2 of n-propyl), 1.19 (3H, d, J = 7.0 Hz, CH3 from [1,4] thiazepin ring), 
 
728 0.95 (3H, t, J = 7.45 Hz, CH3 of n-propyl); Observable minor isomer peaks are at 9.84 
 
729 (1H, s, NH from sec.amide), 7.13 (2H, d, J = 8.64 Hz, Ar-H), 6.86 (2H, d, J = 8.72 Hz, 
 
730 Ar-H), 5.30 (1H, s, methine from [1, 4] thiazepin ring), 3.90 (2H, t, J = 6.56 Hz, OCH2 
 
731 of n-propyl), 3.23 (1H, q, J = 7.17 Hz this peak is partly covered by water peak from 
 
732 DMSO), 1.76-1.62 (2H, m, CH2 of n-propyl), 1.06 (3H, d, J = 7.20 Hz, CH3 from [1, 4] 
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733 
 
734 
thiazepin ring), 0.97 (3H, t, J = 7.47 Hz, CH3  of n-propyl);  HRMS; m/z (ES): found 
332.1428 (C17H22N3O2S [M + H]+) requires 332.1354. 
 
735 
 
736 
4-(4-Allyloxy-phenyl)-3,6-dimethyl-4,8-dihydro-1H-pyrazolo[3,4-e][1,4]thiazepin-7-one 
(1q). Mixture of two isomers (97:3), δH/ppm (400 MHz, d6-DMSO): major isomer 
737 peaks are at 12.31 (1H, s, NH from 3-pyrazole ring), 9.65 (1H, s, NH from sec.amide), 
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738 
 
7.17 (2H, d, J = 8.7 Hz, Ar-H), 6.85 (2H, d, J = 8.7 Hz, Ar-H), 6.09-5.94 (1H, m, =CH of 
 
739 
 
740 
 
741 
 
742 
 
743 
allyl), 5.55 (1H, s, methine from [1, 4] thiazepin ring), 5.37 [1H, dq, J = 1.71 + 17.25 
Hz, =CH2 (Ha-terminal vinyl proton on SP2 carbon)], 5.23 [1H, dq, J = 1.4/1.6 + 10.5 
Hz, =CH2 (Hb-terminal vinyl proton on SP2 carbon)], 4.52 [1H, t, J = 1.48, O-CH2 (Ha- 
allyl proton adjacent to SP2  carbon)], 4.51 [1H, t, J = 1.48, O-CH2  (Hb-allyl proton 
 
adjacent to SP2 carbon)], 3.67 (1H, q, J = 7.1 Hz, methine from [1, 4] thiazepin ring), 
 
744 1.90 (3H, s, CH3 from pyrazole ring), 1.19 (3H, d, J = 7.1 Hz, CH3 from [1,4] thiazepin 
 
745 ring), Observable minor isomer peaks are at 9.84 (1H, s, NH from sec.amide), 6.87 
 
746 (2H, d, J = 8.72 Hz, Ar-H), 5.31 (1H, s, methine from [1, 4] thiazepin ring), 1.67 (3H, s, 
 
747 
 
748 
CH3  from pyrazole ring), 1.07 (2H, d, J = 7.1 Hz, CH3  from [1, 4] thiazepin ring), 
HRMS; m/z (ES): found 330.1272 (C17H20N3O2S [M + H]+) requires 330.4180. 
 
749 Compounds preparation: Benznidazole (Bz) (N-benzyl-2-nitroimidazole-1- 
 
750 acetamide)  was  obtained  from  the  Pharmaceutical  Laboratory  of  the  State  of 
 
751 Pernambuco (LAFEPE, Brazil) and used in all trials as reference drug. All the CYP51 
 
752 inhibitor  compounds  were  purchased  from  Asinex  commercial  vendor,  diluted  in 
 
753 dimethylsulfoxide (DMSO - in vitro) or in trappsol (in vivo) not reaching vehicle levels 
 
754 above 0.6 % and 20 % for in vitro and in vivo assays, respectively. 
 
 
755 T. cruzi parasites: Bloodstream trypomastigotes (BT - Y strain) were obtained from 
 
756 heart  puncture  of  infected  male  Swiss  Webster  mice  at  parasitemia  peak.  The 
 
757 parasites were purified and resuspended in RPMI 1640 medium (pH 7.2 to 7.4) 
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758 without phenol red (Gibco BRL) supplemented with 10% fetal bovine serum (FBS) and 
 
759 2 mM glutamine, as reported previously [26, 27] The analysis upon intracellular forms 
 
760 T. cruzi (Tulahuen strain transfected with Escherichia coli β-galactosidase gene) [28] 
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761 
 
was conducted using L929 cell lineages that were infected with tissue culture-derived 
 
762 trypomastigotes using a 10:1 parasite/ host cell ratio [27]. 
 
 
763 In vitro assays 
 
 
764 Mammalian cell culture: The cardiac cells (CC) were obtained from Swiss embryos 
 
765 Webster mice as described by Meirelles and coworkers [29], and seeded 96 well plate. 
 
766 The cardiac cell cultures were stored at 37°C in Du lbecco’s modified Eagle medium 
 
767 (DMEM; without phenol red; Sigma-Aldrich) supplemented with 5% fetal bovine serum, 
 
768 
 
769 
2.5 mM CaCl2, 1 mM L-glutamine, streptomycin, and 2% chicken embryo extract [22, 
29]. Moreover, L929 fibroblastic cells were cultivated (4 x103  cells/well in 96-well 
770 microplates) at 37°C in RPMI 1640 medium (pH 7.2 to 7.4) without phenol red (Gibco 
 
771 BRL) supplemented with 10% fetal bovine serum and 1% glutamine, as reported 
 
772 previously [27, 30]. 
 
 
773 Cytotoxicity assays: To evaluate the toxicity profile and determine the selectivity 
 
774 index (SI), cardiac and L929 cells were incubated at 37°C with crescent 
 
775 concentrations of the studied compounds for 24 and 96 h and cellular viability were 
 
776 evaluated by colorimetric analysis using Prestoblue [27] and Alamarblue [30] assays 
 
777 as reported, respectively. After 5 and 6 h of incubation respectively, the absorbance 
 
778 were measured at 570 and 600 nm according to manufactures instructions and the 
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779 results confirmed by the analysis of morphology and physiology aspects through light 
 
780 microscopy.  The  results  are  expressed  as  the  percent  of  reduced  viability  in 
 
781 compound-treated  and  vehicle-treated  samples  by  following  the  manufacturer’s 
 
782 instructions and the EC50  values calculated (concentration that reduces the cellular 
 
783 viability by 50%) [26, 27, 30]. 
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784 
 
Trypanocidal effects: BT forms of Y strain (5x106/mL) were incubated for 2 and 24 h 
 
785 at 37°C in absence or presence of crescent concentr ations (0 – 50 µM) of each tested 
 
786 compound.  The  compounds  were  diluted  in  RPMI  1640  medium  (Roswell  Park 
 
787 Memorial Institute - Sigma Aldrich – USA) supplemented with 5% FBS. Subsequently 
 
788 the incubation, death rates were assessed by light microscopy quantification using a 
 
789 Neubauer chamber to determine the EC50 that correspond the compound 
 
790 concentration that reduces in 50% of the number of the parasite population [26,27, 
 
791 31]. For the effect against intracellular forms (Tulahuen-β-galactosidase strain), L929 
 
792 cells were infected for 2h, rinsed using saline to remove non-internalized parasites and 
 
793 then incubated for 48 h at 37°C to establish the cu lture infection. The infected L929 
 
794 cell cultures were exposed first to a fixed concentration of tested compounds (10-12 
 
795 µM). Those that presented ≥ 50 % of reductions in the parasite load, were further 
 
796 screened using infected cultures submitted increasing non-toxic concentrations of the 
 
797 selected  compounds  to  determine  the  EC50   values. Next,  the  absorbance  was 
 
798 measured at 570 nm and results expressed as the percentage of T. cruzi growth 
 
799 inhibition in compound-tested cells compared  to untreated  cells. In parallel, the 
 
800 therapy using the reference drug (Bz) was always performed as reported [26]. 
 
 
 
801 In vivo assay 
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802 Acute toxicity: NOAEL (no-observed-adverse-effect level) was obtained by injecting, 
 
803 via intraperitoneal (ip), increasing concentrations of the tested compound (up to 200 
 
804 mg/kg of mice body weight) in female Swiss Webster mice (weight, 20 to 23 g; n - 2 
 
805 mice per assay for two assays). Treated animals were inspected for toxic and subtoxic 
 
806 symptoms according to the Organization for Economic Cooperation and Development 
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807 
 
(OECD)  guidelines.  At  48  h  after  compound  injection,  the  NOAEL  values  were 
 
808 determined as reported previously [31]. 
 
 
809 Mice infection and treatment schemes: Male Swiss Webster mice (18 to 20 g) 
 
810 obtained from the animal facilities of Instituto de Ciência e Tecnologia em Biomodelos 
 
811 (ICTB) from Fundação Oswaldo Cruz (FIOCRUZ) were household at a maximum of 6 
 
812 animals per cage, and kept in a specific-pathogen-free (SPF) room at 20 to 24°C 
 
813 under a 12- light and 12-h dark cycle, providing sterilized water and chow ad libitum. 
 
814 
 
815 
The animals were acclimated for 7 days before starting the experiments. Infection was 
performed by i.p. injection of 104 bloodstream trypomastigotes (Y strain). Compound 1 
816 was first dissolved in DMSO and then freshly diluted with 20% of Trappsol (CTD, Inc., 
 
817 USA) and Bz was prepared in sterile distilled water with 3% Tween 80 (Sigma- 
 
818 Aldrich). The animals were divided into the following groups: uninfected (noninfected 
 
819 and untreated), untreated (infected with T.cruzi but treated only with vehicle), and 
 
820 treated (infected and treated) i.p. with nontoxic doses of 5 to 20 mg/kg/day test 
 
821 
 
822 
 
823 
compound or with 100 mg/kg/day Bz p.o. The mouse received a 0.1-ml i.p. dose, the 
treatment started at 5th day post infection (dpi) that represent the parasitemia onset in 
this experimental model and followed for five consecutive days, until 9th  dpi. For Bz 
824 treatment,  infected  mice  received  a  0.1  mL  p.o.  following  the  same  therapeutic 
 
825 schemes as described above [19]. 
 
 
39 
  ACCEPTED MANUSCRIPT   
 
826 Parasitemia and mortality rates: Parasitemia was individually detected by Pizzy- 
 
827 Brener [32] methodology using direct light microscopy to quantify the number of 
 
828 parasites in 5µL of blood collected from tail vein, and the mice were checked for 
 
829 mortality daily until 30 days post treatment [31]. Mortality was expressed by the 
 
830 percentage of cumulative mortality (CM) as described by Batista and coworkers [22]. 
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831 
 
Ethics 
 
 
832 All procedures were carried out in accordance with the guidelines established by the 
 
833 FIOCRUZ Committee of Ethics for the Use of Animals (CEUA LW16/14). 
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